Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Market Cap
$444.50M
P/E Ratio
-1.36
1Y Stock Return
-24.82%
1Y Revenue Growth
-24.70%
Dividend Yield
0.00%
Price to Book
1.0
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
STG | -13.67% | $35.67M | +7.92% | 0.00% |
GAN | -13.09% | $83.39M | +21.19% | 0.00% |
PULM | -9.93% | $19.83M | +202.98% | 0.00% |
OXBR | -8.92% | $19.05M | +178.18% | 0.00% |
HUSA | -8.56% | $16.69M | -11.56% | 0.00% |
BTCT | -7.64% | $42.61M | +353.33% | 0.00% |
CHD | -5.82% | $27.18B | +19.50% | 1.03% |
WLKP | -5.73% | $796.39M | +4.00% | 8.34% |
MNOV | -5.65% | $93.19M | +2.15% | 0.00% |
PDD | -5.29% | $163.43B | +0.29% | 0.00% |
COR | -5.10% | $47.48B | +21.20% | 0.86% |
PAM | -4.88% | $4.32B | +86.28% | 0.00% |
TEO | -4.81% | $1.69B | +87.97% | 0.00% |
LQDA | -4.74% | $859.91M | +53.94% | 0.00% |
RDDT | -4.27% | $24.08B | +303.41% | 0.00% |
ADBE | -3.63% | $219.93B | -18.23% | 0.00% |
TEM | -3.47% | $8.50B | 0.00% | 0.00% |
CYD | -3.33% | $364.46M | -2.94% | 4.26% |
TCTM | -2.87% | $8.10M | -42.99% | 0.00% |
CMG | -2.79% | $80.02B | +33.62% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FATE | 56.32% | $248.29M | -11.02% | 0.00% |
CRBU | 55.22% | $180.20M | -62.45% | 0.00% |
NTLA | 54.62% | $1.44B | -50.35% | 0.00% |
CRSP | 53.55% | $4.01B | -30.49% | 0.00% |
BEAM | 51.53% | $2.09B | -9.52% | 0.00% |
VRDN | 50.29% | $1.60B | +28.92% | 0.00% |
ABCL | 49.13% | $800.44M | -37.56% | 0.00% |
EDIT | 48.99% | $204.72M | -75.49% | 0.00% |
DNLI | 47.04% | $3.50B | +33.66% | 0.00% |
PLRX | 46.41% | $778.32M | -9.55% | 0.00% |
PGEN | 44.93% | $228.91M | -28.00% | 0.00% |
TWST | 44.34% | $2.42B | +74.27% | 0.00% |
ALEC | 44.09% | $377.04M | -19.46% | 0.00% |
ACLX | 43.79% | $4.74B | +69.19% | 0.00% |
EYE | 43.64% | $888.30M | -42.18% | 0.00% |
VIR | 42.87% | $954.40M | -26.51% | 0.00% |
RCKT | 42.76% | $1.20B | -39.83% | 0.00% |
RCUS | 41.95% | $1.33B | +5.07% | 0.00% |
ANGO | 41.77% | $273.06M | -0.59% | 0.00% |
SSP | 41.61% | $153.73M | -76.04% | 0.00% |
Yahoo
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in December. The Company is also announcing that the presentation time for the upcoming Jefferies London Healthcare conference on November 20, 2024 has changed. TIME UPDATE
Yahoo
ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine ModelsProprietary Dagger® Technology Enables ALLO-329 to Overcome Rejection and Expand the Presence of Alloreactive T CellsPresented Data Demonstrates that ALLO-329 Could Be Effective in Treating Autoimmune Diseases with Reduced or No Lymphodepleting ChemotherapyALLO-329 Investigational New Drug (IND) Submission Planned for Q1 2025 SOUTH SAN FRAN
Yahoo
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
Yahoo
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.
Yahoo
Allogene Therapeutics Inc (ALLO) reports a strong cash position and promising clinical progress, despite facing competitive and safety hurdles in its pivotal trials.
Finnhub
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer and autoimmune disease, today provided...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PRT | <0.01% | $48.72M | -16.56% | 10.33% |
LITB | -0.05% | $35.48M | -75.45% | 0.00% |
LTM | -0.06% | $8.51B | -100.00% | <0.01% |
LPTH | 0.06% | $62.27M | +33.05% | 0.00% |
ALAR | 0.07% | $89.09M | +158.08% | 0.00% |
DUOL | -0.07% | $14.17B | +49.85% | 0.00% |
VSTA | -0.19% | $204.94M | -39.33% | 0.00% |
MESO | -0.30% | $1.23B | +347.11% | 0.00% |
CANG | 0.32% | $253.50M | +212.50% | 0.00% |
TCOM | -0.34% | $40.41B | +91.40% | 0.00% |
PLG | -0.39% | $173.19M | +67.33% | 0.00% |
SMC | 0.45% | $383.35M | +97.26% | 0.00% |
NGL | 0.45% | $572.94M | +5.60% | 0.00% |
LPLA | -0.45% | $23.55B | +38.13% | 0.38% |
MCK | -0.46% | $78.15B | +35.51% | 0.42% |
NEUE | -0.51% | $40.93M | -34.13% | 0.00% |
TTE | 0.57% | $138.45B | -11.95% | 5.50% |
AMED | -0.75% | $2.95B | -3.95% | 0.00% |
HCI | -0.78% | $1.16B | +29.00% | 1.48% |
CARV | 0.85% | $8.48M | -8.79% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 59.19% | $70.59M | 0.5% |
ARKG | 57.91% | $1.13B | 0.75% |
XBI | 57.70% | $6.58B | 0.35% |
IWC | 56.26% | $933.99M | 0.6% |
IBB | 53.88% | $6.66B | 0.45% |
PBE | 53.26% | $258.53M | 0.58% |
IWM | 52.95% | $75.73B | 0.19% |
VTWO | 52.94% | $12.38B | 0.1% |
IWO | 52.79% | $12.56B | 0.24% |
XPH | 51.14% | $157.87M | 0.35% |
XSHD | 51.06% | $54.49M | 0.3% |
IWN | 50.95% | $13.17B | 0.24% |
PTH | 50.76% | $143.31M | 0.6% |
GSSC | 50.60% | $529.86M | 0.2% |
ESML | 50.50% | $1.90B | 0.17% |
PRFZ | 50.48% | $2.65B | 0.39% |
NUSC | 50.44% | $1.27B | 0.31% |
REGL | 50.31% | $1.65B | 0.4% |
BSVO | 50.21% | $1.53B | 0.47% |
MDYV | 50.17% | $3.25B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
MINT | -0.09% | $11.62B | 0.35% |
CANE | 0.25% | $17.72M | 0.29% |
UNG | 0.35% | $908.80M | 1.06% |
SOYB | 0.40% | $27.32M | 0.22% |
DUSB | 0.45% | $797.63M | 0.15% |
SHV | 1.03% | $18.13B | 0.15% |
XHLF | -1.06% | $874.27M | 0.03% |
JBBB | 1.18% | $1.26B | 0.49% |
USCI | 1.23% | $185.47M | 1.07% |
CSHI | -1.39% | $482.85M | 0.38% |
IBMM | 1.40% | $391.28M | 0.18% |
FTGC | 1.63% | $2.17B | 1.02% |
TBIL | -1.69% | $4.38B | 0.15% |
BCI | 1.71% | $1.20B | 0.26% |
SGOV | -1.94% | $27.53B | 0.09% |
GBIL | 2.05% | $5.60B | 0.12% |
DBA | -2.14% | $755.88M | 0.93% |
FLRN | 2.68% | $2.33B | 0.15% |
AGZD | -2.91% | $142.76M | 0.23% |
KRBN | -2.98% | $242.47M | 0.85% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -35.42% | $388.04M | 1.43% |
VIXY | -22.80% | $195.31M | 0.85% |
DBE | -14.93% | $50.13M | 0.77% |
USDU | -14.75% | $201.97M | 0.5% |
DBO | -13.52% | $217.57M | 0.77% |
UUP | -12.58% | $309.25M | 0.77% |
EQLS | -12.50% | $76.08M | 1% |
CTA | -12.09% | $350.27M | 0.78% |
KMLM | -11.78% | $353.87M | 0.9% |
COMT | -11.72% | $829.06M | 0.48% |
WEAT | -11.11% | $120.27M | 0.28% |
KCCA | -8.75% | $220.51M | 0.87% |
GSG | -5.12% | $914.42M | 0.75% |
JUCY | -4.79% | $324.29M | 0.6% |
PDBC | -4.45% | $4.40B | 0.59% |
HDRO | -3.87% | $164.26M | 0.3% |
BILZ | -3.81% | $563.02M | 0.14% |
BOXX | -3.69% | $4.43B | 0.1949% |
TPMN | -3.65% | $40.60M | 0.65% |
TAIL | -3.63% | $67.98M | 0.59% |
Current Value
$2.111 Year Return
Current Value
$2.111 Year Return